YH-25724 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how YH-25724’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YH-25724 is under development for the treatment of non-alcoholic steatohepatitis (NASH), obesity and non-alcoholic fatty liver disease (NAFLD). It is administered through subcutaneous route. It acts by targeting fibroblast growth factor 21 (FGF21) and glucagon like peptide 1 (GLP1) receptors. The drug candidate is developed based on hybrid Fc fusion protein platform technology.
It was also under development for the treatment of type 2 diabetes.
Boehringer Ingelheim International overview
Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets of pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for Swine, Ruminant, Poultry, Horses, Pets etc. It operates facilities for manufacture pharmaceuticals and medical products. Boehringer is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.
For a complete picture of YH-25724’s drug-specific PTSR and LoA scores, buy the report here.